Although current guidelines recommend delaying noncardiac surgery for 6 to 12 months after drug-eluting stent implantation, new data suggest surgery may be performed earlier.
Your search for comorbidities returned 12 results
Click on a filter below to refine your search. Remove a filter to broaden your search.
Drug-eluting stents in percutaneous coronary intervention appear to be safer in patients with end-stage renal disease compared with bare-metal stents.
In an observational study of the ADAPT-DES trial, high platelet reactivity was associated with adverse ischemic events in patients undergoing percutaneous coronary intervention.
This simple scoring system stratified risk at 30 days and 1 year into low-risk, moderate-risk, and high-risk categories.
Adjusted hazard ratios for mortality suggested similar outcomes in carotid artery stenting and carotid endarterectomy.
Native coronary artery PCI produced better outcomes in patients with previous CABG.
Aortic valve gradient was independently associated with 1-year mortality and recurrent heart failure, after adjustment, in patients undergoing transcatheter aortic valve replacement.
No differences between monotherapy and multiple anthrombotic therapy in rates of stroke, MACE, or death.